CD19-CAR自然杀伤细胞疗法在CD20耐药非霍奇金淋巴瘤中的相互作用动力学及转录组和分泌反应
研究探讨了CD19-CAR-NK92疗法在淋巴瘤细胞系(包括抗CD20耐药细胞)、患者来源细胞和人源异种移植模型中的溶细胞和机制活性。结果显示该疗法显著增加溶细胞活性并诱导凋亡,耐药细胞需要更长接触时间,转录组分析揭示IFNγ信号等通路激活。
要点
- CD19-CAR-NK92在敏感和耐药的淋巴瘤细胞中均显示出有效的抗淋巴瘤活性。
- 抗CD20耐药细胞系需要更长的接触时间才能被杀死。
- 共培养后淋巴瘤细胞显示IFNγ信号、凋亡执行等通路的保守激活。
核心结论
- CD19-CAR-NK92在多种敏感和耐药的淋巴瘤细胞中表现出强效抗淋巴瘤活性,涉及不同的免疫生物学细胞死亡机制。
研究设计与样本
- 研究使用淋巴瘤细胞系(弥漫大B细胞、滤泡和伯基特淋巴瘤),包括利妥昔单抗和奥妥珠单抗耐药细胞、患者来源细胞和人源异种移植模型。
主要发现
- CD19-CAR-NK92在效靶比1:1-10:1时通过LDH释放显著增加溶细胞活性并诱导凋亡,包括抗CD20耐药淋巴瘤细胞。
- 单细胞微流体分析显示大多数淋巴瘤细胞被单次接触杀死,抗CD20耐药细胞系需要显著更长的接触时间。
- 转录组分析显示与CD19-CAR-NK92共培养的淋巴瘤细胞中IFNγ信号、凋亡执行、配体结合、免疫调节和趋化因子信号通路保守激活。
- 92重细胞因子面板分析显示抗CD20耐药SUDHL4细胞中颗粒酶、FASL、CCL3和IL10分泌增加,并诱导mTOR和G2/M检查点激活相关基因。
临床怎么用
- CD19-CAR-NK92疗法可能对CD20耐药非霍奇金淋巴瘤有效,需关注耐药细胞需要更长接触时间的动力学特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We investigated the cytolytic and mechanistic activity of anti-CD19 chimeric antigen receptor natural killer (CD19.CAR.NK92) therapy in lymphoma cell lines (diffuse large B-cell, follicular, and Burkitt lymphoma), including rituximab- and obinutuzumab-resistant cells, patient-derived cells, and a human xenograft model. CD19.CAR.NK92 therapy significantly increased cytolytic activity at E:T ratios (1:1-10:1) via LDH release and prominent induction of apoptosis in all cell lines, including in anti-CD20 resistant lymphoma cells. The kinetics of CD19.CAR.NK92 cell death measured via droplet-based single cell microfluidics analysis showed that most lymphoma cells were killed by single contact, with anti-CD20 resistant cell lines requiring significantly longer contact duration with NK cells. In addition, systems biology transcriptomic analyses of flow-sorted lymphoma cells co-cultured with CD19.CAR.NK92 revealed conserved activation of IFNγ signaling, execution of apoptosis, ligand binding, and immunoregulatory and chemokine signaling pathways. Furthermore, a 92-plex cytokine panel analysis showed increased secretion of granzymes, increased secretion of FASL, CCL3, and IL10 in anti-CD20 resistant SUDHL4 cells with induction of genes relevant to mTOR and G2/M checkpoint activation, which were noted in all anti-CD20 resistant cells co-cultured with CD19.CAR.NK92 cells. Collectively, CD19.CAR.NK92 was associated with potent anti-lymphoma activity across a host of sensitive and resistant lymphoma cells that involved distinct immuno-biologic mechanisms of cell death.
引用
- Ravi D, Sarkar S, Purvey S, et al. Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma. Leukemia. 2019. PMID: 31772298. doi:10.1038/s41375-019-0663-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。